Your browser doesn't support javascript.
loading
GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines.
Micoli, Francesca; Alfini, Renzo; Di Benedetto, Roberta; Necchi, Francesca; Schiavo, Fabiola; Mancini, Francesca; Carducci, Martina; Palmieri, Elena; Balocchi, Cristiana; Gasperini, Gianmarco; Brunelli, Brunella; Costantino, Paolo; Adamo, Roberto; Piccioli, Diego; Saul, Allan.
Afiliación
  • Micoli F; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Alfini R; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Di Benedetto R; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Necchi F; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Schiavo F; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Mancini F; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Carducci M; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Palmieri E; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Balocchi C; GSK, 53100 Siena, Italy.
  • Gasperini G; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
  • Brunelli B; GSK, 53100 Siena, Italy.
  • Costantino P; GSK, 53100 Siena, Italy.
  • Adamo R; GSK, 53100 Siena, Italy.
  • Piccioli D; GSK, 53100 Siena, Italy.
  • Saul A; GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
Vaccines (Basel) ; 8(3)2020 Sep 17.
Article en En | MEDLINE | ID: mdl-32957610
Technology platforms are an important strategy to facilitate the design, development and implementation of vaccines to combat high-burden diseases that are still a threat for human populations, especially in low- and middle-income countries, and to address the increasing number and global distribution of pathogens resistant to antimicrobial drugs. Generalized Modules for Membrane Antigens (GMMA), outer membrane vesicles derived from engineered Gram-negative bacteria, represent an attractive technology to design affordable vaccines. Here, we show that GMMA, decorated with heterologous polysaccharide or protein antigens, leads to a strong and effective antigen-specific humoral immune response in mice. Importantly, GMMA promote enhanced immunogenicity compared to traditional formulations (e.g., recombinant proteins and glycoconjugate vaccines), without negative impact to the anti-GMMA immune response. Our findings support the use of GMMA as a "plug and play" technology for the development of effective combination vaccines targeting different bugs at the same time.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Italia